Indegene

Indegene is aggressively contextualizing GenAI through its proprietary Cortex platform, moving beyond pilots to production. Its Tectonic offering, which focuses on upstream creative processes, generated $2 million in H1 FY26 from 4 paying customers, up from 2 in Q1. Management believes real value in GenAI comes from domain-specific knowledge engineering rather than generic models.

The acquisition of BioPharm for $65 million adds downstream omnichannel campaign execution capabilities, while WARN & CO (£2M upfront) brings UK-based boutique consulting expertise. These acquisitions are expected to be integrated over 2-6 quarters. While they will cause a near-term margin drag of ~1.5%, they are viewed as essential for capturing enterprise-wide commercial engagements.

Q2 margins were impacted by a 2.1% dilution from annual wage hikes effective July 1, 2025. Additionally, the company spent $0.5 million on M&A diligence, $0.5 million on its flagship IDS 2025 event in Philadelphia, and $0.25 million on technology/GenAI subscriptions. Management expects these 'ahead of the curve' investments to compress margins in the short term but drive operating leverage by FY27.

The Enterprise segment, contributing 88.5% of revenue, grew 8.1% QoQ, demonstrating strong demand for medical and commercial solutions. Conversely, Brand Activation degrew 15.8% due to the completion of a large project in Q1. Management highlighted a healthy pipeline in Brand Activation and expects a significant ramp-up in Q3 to mitigate recent declines.

Management addressed evolving U.S. policies, including MFN drug pricing and potential pharma tariffs. They argued that the industry is regaining value as regulatory uncertainty clears. Indegene expects to benefit from tighter DTC marketing regulations as pharma spend shifts from traditional media (TV/print) to the digital and HCP channels where Indegene specializes.